NASDAQ:CHRS

Coherus BioSciences (CHRS) Stock Forecast, Price & News

$4.46

+0.32 (+7.73%)

(As of 09/22/2023 ET)

Compare

Today's Range: $4.14
▼
$4.48
50-Day Range: $4.14
▼
$5.45
52-Week Range: $3.60
▼
$10.99

Volume: 2.71 million shs
Average Volume: 3.56 million shs
Market Capitalization: $421.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.63

Coherus BioSciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 227.9% Upside
$14.63 Price Target
Short Interest: Bearish
16.57% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.08
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.97) to $0.03 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

333rd out of 963 stocks

Biological Products, Except Diagnostic Industry

51st out of 158 stocks

3.4

Analyst's Opinion

Consensus Rating
Coherus BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.63, Coherus BioSciences has a forecasted upside of 227.9% from its current price of $4.46.
Amount of Analyst Coverage
Coherus BioSciences has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
16.57% of the outstanding shares of Coherus BioSciences have been sold short.
Short Interest Ratio / Days to Cover
Coherus BioSciences has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Coherus BioSciences has recently decreased by 0.32%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Coherus BioSciences does not currently pay a dividend.
Dividend Growth
Coherus BioSciences does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Coherus BioSciences has received a 69.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Pegfilgrastim", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Coherus BioSciences is -1.08.

2.8

News and Social Media Coverage

News Sentiment
Coherus BioSciences has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Coherus BioSciences this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for CHRS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Coherus BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Coherus BioSciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.99% of the stock of Coherus BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
91.86% of the stock of Coherus BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Coherus BioSciences are expected to grow in the coming year, from ($1.97) to $0.03 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Coherus BioSciences is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Coherus BioSciences is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Coherus BioSciences (NASDAQ:CHRS) Stock

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CHRS Price History

30 days | 90 days | 365 days | Advanced Chart

CHRS Stock News Headlines

September 24, 2023 | americanbankingnews.com

Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Moderate Buy" by Analysts

September 15, 2023 | finance.yahoo.com

With 72% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big guns

September 24, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

September 8, 2023 | msn.com

Why Coherus BioSciences Stock Was Plunging This Week

September 1, 2023 | finance.yahoo.com

Coherus BioSciences to Participate at Upcoming September Investor Conferences

September 1, 2023 | finance.yahoo.com

Coherus BioSciences to Participate at Upcoming September Investor Conferences

August 31, 2023 | finance.yahoo.com

Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences

August 15, 2023 | msn.com

Surface Oncology And Coherus BioSciences: Does A Buyout Equal A Good Deal?

September 24, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

August 3, 2023 | markets.businessinsider.com

Analyst Ratings for Coherus BioSciences

August 3, 2023 | finance.yahoo.com

Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights

August 3, 2023 | seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q2 2023 Earnings Call Transcript

July 26, 2023 | finance.yahoo.com

Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023

July 24, 2023 | msn.com

Citigroup Initiates Coverage of Coherus Biosciences (CHRS) with Buy Recommendation

July 23, 2023 | seekingalpha.com

Coherus: 'Hold' As Biosimilar Growth Initiatives Play Out

July 20, 2023 | finance.yahoo.com

Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

July 14, 2023 | markets.businessinsider.com

10 Analysts Have This to Say About Coherus BioSciences

July 14, 2023 | msn.com

Truist Securities Maintains Coherus Biosciences (CHRS) Buy Recommendation

July 13, 2023 | finance.yahoo.com

Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™

July 6, 2023 | msn.com

Coherus Biosciences (CHRS) Price Target Decreased by 8.39% to 14.72

July 6, 2023 | seekingalpha.com

Coherus: Why I Am Exiting, But Also Why You May Want To Hold On

July 3, 2023 | markets.businessinsider.com

Coherus Rolls Out YUSIMRY At $995 Per Carton In US

July 3, 2023 | finance.yahoo.com

UPDATE 1-Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira

June 29, 2023 | msn.com

Truist Securities Reiterates Coherus Biosciences (CHRS) Buy Recommendation

June 27, 2023 | markets.businessinsider.com

Credit Suisse Remains a Buy on Coherus Biosciences (CHRS)

June 20, 2023 | markets.businessinsider.com

Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability

June 20, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Coherus Biosciences (CHRS)

See More Headlines

Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Company Calendar

Last Earnings: 8/02/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CHRS
CUSIP: N/A
CIK: 1512762
Web: www.coherus.com
Phone: (650) 649-3530
Fax: N/A
Employees: 294
Year Founded: 2010

Price Target and Rating

Average Stock Price Forecast: $14.63
High Stock Price Forecast: $23.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +227.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-291,750,000.00
Net Margins: -145.18%
Pretax Margin: -145.18%
Return on Equity: N/A
Return on Assets: -54.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.28
Quick Ratio: 1.90

Sales & Book Value

Annual Sales: $211.04 million
Price / Sales: 2.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.77) per share
Price / Book: -2.52

Miscellaneous

Outstanding Shares: 94,470,000
Free Float: 84,086,000
Market Cap: $421.34 million
Optionable: Optionable
Beta: 0.88

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Dennis M. Lanfear (Age 68)
Chairman, Pres & CEO
Comp: $1.79M

Mr. McDavid Stilwell (Age 51)
Chief Financial Officer
Comp: $719.64k

Mr. Bryan J. Mcmichael (Age 45)
Sr. VP of Accounting, Principal Accounting Officer & Corp. Controller

Mr. Richard L. Hameister
Chief Technical Officer

Mr. Marek Ciszewski J.D.
Sr. VP of Investor Relations

Mr. Christopher W. Slavinsky (Age 50)
Chief Bus. & Legal Officer

Cheston Turbyfill
VP of Communications

Ms. Rebecca Sunshine (Age 60)
Chief HR Officer

Mr. Michael Chen
Sr. VP of Commercial Analytics & Trade

Mr. Paul Reider (Age 54)
Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CHRS Stock - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CHRS shares.
View CHRS analyst ratings or view top-rated stocks.
What is Coherus BioSciences' stock price forecast for 2023?: 7 equities research analysts have issued twelve-month price objectives for Coherus BioSciences' stock. Their CHRS share price forecasts range from $8.00 to $23.00. On average, they expect the company's stock price to reach $14.63 in the next twelve months. This suggests a possible upside of 227.9% from the stock's current price.
View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts.
How have CHRS shares performed in 2023?: Coherus BioSciences' stock was trading at $7.92 at the start of the year. Since then, CHRS stock has decreased by 43.7% and is now trading at $4.46.
View the best growth stocks for 2023 here.
When is Coherus BioSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CHRS earnings forecast.
How were Coherus BioSciences' earnings last quarter?: Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.17. The biotechnology company had revenue of $58.72 million for the quarter, compared to analyst estimates of $50.83 million.
What ETFs hold Coherus BioSciences' stock?: ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).First Trust Innovation Leaders ETF (ILDR).
What guidance has Coherus BioSciences issued on next quarter's earnings?: Coherus BioSciences updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275.00M-, compared to the consensus revenue estimate of $266.16 million.
What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?: 21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).
What is Coherus BioSciences' stock symbol?: Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."
Who are Coherus BioSciences' major shareholders?: Coherus BioSciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (16.71%), State Street Corp (2.70%), Aristotle Capital Boston LLC (2.44%), Marshall Wace LLP (2.42%), C WorldWide Group Holding A S (2.39%) and Peregrine Capital Management LLC (1.78%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends.
How do I buy shares of Coherus BioSciences?: Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Coherus BioSciences' stock price today?: One share of CHRS stock can currently be purchased for approximately $4.46.
How much money does Coherus BioSciences make?: Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $421.34 million and generates $211.04 million in revenue each year. The biotechnology company earns $-291,750,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.
How many employees does Coherus BioSciences have?: The company employs 294 workers across the globe.
Does Coherus BioSciences have any subsidiaries?: The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More
How can I contact Coherus BioSciences?: Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.

This page (NASDAQ:CHRS) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial